AstraZeneca Full year and Q4 2023 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rebounds, but yield surge sets stage for weekly losses
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
AstraZeneca's earnings top estimates but shares fall on core operating profit drop
February 8, 2024 6:41 AM ESTAstraZeneca (NASDAQ: AZN) shares fell more than 6% in premarket trading Thursday after the drugmaker reported notably lower-than-expected core operating profit for the fourth quarter.
Earnings per share (EPS) came in at $1.45 in Q4, topping the forecasted $0.74. The pharmaceutical giant generated a quarterly revenue of $12.02 billion, also above the consensus estimate of $12 billion.
Core operating profit rose 5.4% year-over-year to $2.75 billion, but was... More
Deutsche Bank Downgrades AstraZeneca (AZN) to Hold
February 8, 2024 5:37 AM ESTDeutsche Bank analyst Emmanuel Papadakis downgraded AstraZeneca (NASDAQ: AZN) from Buy to Hold.
The analyst comments "Q4 is a thoroughly underwhelming end to 2023 with a soft print that missed in most of the places that matter (Enhertu included, again), whilst FY24 guidance is... More
